

Joint UKBTS Professional Advisory Committee (¹) Summary Sheet

1. Paper for the JPAC meeting on:	14 November 2013
2. Date submitted:	31 October 2013
3. Title (including version no.):	Tamoxifen or Raloxifene for breast cancer prevention
4. Author(s):	Dr Sue Barnes, Chair of the SAC on Care and Selection of Donors
5. Brief summary:	<p>New guidelines from National Institute for Health and Care Excellence (NICE) - says women in England and Wales who are aged over 35 and at "moderate" or "high" risk of breast cancer as a result of their family history or genes should be considered for preventative drug therapy. By this they mean women with at least a one in six chance of developing the disease. NICE says tamoxifen or raloxifene taken daily for five years can cut breast cancer risk by 40%. The decision about the best treatment should be a joint one between the patient and the medical team. NICE are the first in Europe to recommend that healthy women are given drugs to prevent breast cancer.</p> <p>It is likely that Northern Ireland will soon follow suit.</p> <p>The Scottish government says women with two or more family members who have had breast cancer will be offered the treatment for five years. It was announced last month that genetic testing would also be offered in Scotland to those with a 10% risk of a faulty gene.</p> <p>We recommend that the Malignancy entry is further amended to add under a further discretion:</p> <p><i>e) Potential donors with a high risk of cancer due to family history or following genetic tests, even if had or having surgery or on prophylactic medication (e.g. Tamoxifen), accept.</i></p> <p><i>See if Relevant</i></p> <p><u>Surgery</u></p>
6. Action required by the JPAC: (What do you want JPAC to do in response to this paper?) e.g. <ul style="list-style-type: none"> • endorse a specific recommendation • advise where there is a choice of possible actions • advise on priorities within the work plan • provide a steer on policy 	Discuss and approve recommendation
7. Any other relevant information:	

(¹) Joint United Kingdom Blood Transfusion Services Professional Advisory Committee